This page describes pharmacological agents that may have legal restrictions, side effects, and drug interactions in your jurisdiction. Information is for educational research only — consult a clinician before considering any compound.
Clonidine
Generic, cheap, non-selective α2-adrenergic agonist that shuts down central sympathetic outflow — heavy sedation, lower BP, slower HR,…
Aliases (6)
Overview
What is Clonidine?
Clonidine is a centrally acting alpha-2 adrenergic agonist developed in the 1960s for hypertension. Originally an antihypertensive, it is now used off-label for ADHD (especially sleep onset), opioid withdrawal, and PTSD nightmares.
Key Benefits
Lowers blood pressure, sedates and reduces hyperarousal, mitigates ADHD-related sleep onset insomnia, suppresses autonomic withdrawal symptoms, and dampens hot flashes. Useful as a downer/anchor when stimulants disturb sleep.
Mechanism of Action
Acts as a presynaptic alpha-2 adrenergic receptor agonist in the brainstem (locus coeruleus and rostral ventrolateral medulla), suppressing sympathetic outflow and reducing norepinephrine release. Net effect: lower BP, slower HR, reduced arousal, sedation.
▸Brand options6 known
StatusPrescription-only (US, EU, UK, AU, CA); not DEA-scheduled
Research Protocols
Disclaimer: These are commonly discussed research protocols and not medical advice.
Peptide Interactions
orthogonal mechanism, on-label combination, useful for residual symptoms, stimulant-induced overarousal, and sleep onset disruption. Not relevant-to-archetyp…
clonidine clamps autonomic withdrawal symptoms while opioid is tapered; standard practice.
additive sedation/anxiolysis, used clinically in detox protocols.
pharmacologic + behavioral combination.
Same problem as guanfacine — clonidine would actively undercut modafinil's wakefulness signal. For the user, this is the load-bearing reason clonidine is wro…
additive sedation, respiratory depression risk. Particularly dangerous in overdose.
additive BP-lowering and bradycardia.
if both are on board and either is stopped abruptly, rebound effects are amplified by the remaining drug. Don't stack.
No reason to use both.
TCAs blunt the antihypertensive effect of clonidine via central NE reuptake inhibition (raising synaptic NE that competes with the α2 agonism). Clinical rele…
theoretical risk of hypertensive crisis if MAOI is non-selective; with selegiline at MAO-B-selective doses (the user's V stack conditional), risk is minimal.…
the dynamic of "stim + clonidine to mitigate stim" is real but should be supervised; off-label self-experimentation invites bad outcomes.
Quality Indicators
Pharmacy-dispensed, intact packaging
Prescription tablets in original sealed packaging from a licensed pharmacy.
Generic vs branded
Generics are usually fine but bioavailability can vary slightly; track if you switch.
Unbranded blister or counterfeit risk
Counterfeit pharmaceuticals are a known issue; verify pharmacy and lot if buying internationally.
What to Expect
- Day 1PK-driven acute peak per administration. Verify dose tolerated.
- Week 1Steady-state reached for most daily-dosed pharma.
- Week 2-4Therapeutic effect established; titration window if needed.
- Long-termPeriodic monitoring per drug class (labs, BP, ECG as applicable).
Side Effects & Safety 14
Side Effects
- 1Sedation / drowsiness: 30-50% — dominant effect; reason clonidine is reserved for use cases where sedation is acceptable or desirable.
- 2Dry mouth: 40% — α2-mediated reduction in salivation; can be severe.
- 3Dizziness / lightheadedness: 15-20% — often orthostatic.
- 4Constipation: 10-15%
- 5Fatigue: 10-15%
- 6Headache: 10%
- 7Hypotension / orthostatic hypotension: 10-25% depending on dose.
- 8Bradycardia — clinically relevant in some, monitor HR. Can cause syncope at high doses or in volume-depleted patients.
- 9Erectile dysfunction at chronic dose
- 10Nausea
- 11Nightmares / vivid dreams — paradoxical at low doses, less common than with chronic clonidine
- 12Depression / depressive mood — known concern at chronic dose
- 13Insomnia — paradoxical in some users despite sedating profile (often after the initial 4-6 hr sedation lifts)
- 14Anxiety on dose-tapering — anticipatory or rebound
When to Stop
- Severe hypotension / syncope — particularly with overdose, rapid IV administration, or co-administration with other antihypertensives.
- Severe bradycardia / AV block — case reports; relevant in patients with pre-existing conduction disease.
- Rebound hypertension on abrupt withdrawal — THE signature serious risk. Chronic users (≥1-2 weeks daily) who stop abruptly can develop rebound BP spikes 12-48 hr post-cessation, often accompanied by tachycardia, anxiety, tremor, sweating, headache. Severity correlates with duration of use and dose. Documented MIs, strokes, hypertensive emergencies in chronic users who stopped without taper. Guanfacine has the same risk but milder (longer half-life smooths the falloff); clonidine is the bigger offender. Always taper.
- Pediatric overdose — heavily over-represented in poison-control data; small ingestions (1-2 tablets) can cause severe toxicity in young children. Household safety concern when prescribed for ADHD.
- Coma / respiratory depression in overdose — particularly when combined with other CNS depressants (opioids, benzos, alcohol).
- Allergic contact dermatitis with patch (Catapres-TTS) — local skin reactions in 15-20% of patch users.
- Withdrawal-induced encephalopathy — case reports in severe withdrawal.
- First 1-2 weeks of daily dosing: sedation, orthostatic episodes, dry mouth peak.
- Dose increases: re-watch BP/HR for 1 week after each step.
- Discontinuation after any chronic exposure: taper over 1-2+ weeks; monitor BP daily for 2 weeks post-cessation.
- Concurrent illness with volume depletion (gastroenteritis, dehydration): clonidine + reduced volume = severe hypotension risk.
References
Clonidine — Wikipedia
overview of indications, history, brand names, mechanism
View StudyCatapres (clonidine HCl tablets) prescribing information (FDA, Boehringer Ingelheim)
full label
View StudyKapvay (clonidine HCl extended-release tablets) prescribing information (FDA)
ER formulation pediatric ADHD label
View StudyJain et al. 2011 — Clonidine ER monotherapy for pediatric ADHD pivotal trial (J Am Acad Child Adolesc Psychiatry)
pivotal Kapvay ER ADHD trial
View StudyKollins et al. 2011 — Clonidine ER as adjunct to stimulants for pediatric ADHD (Pediatrics)
adjunct trial
View StudyJäkälä et al. 1999 — Guanfacine, but not clonidine, improves planning and working memory in humans (Neuropsychopharmacology)
the comparative healthy-volunteer trial
View StudyCoull et al. 1995 — Clonidine cognitive effects in healthy adults
cognitive impairment evidence
View StudyPandya et al. 2000 — Clonidine for hot flashes in tamoxifen-treated breast cancer survivors RCT
hot flash A-tier evidence
View StudyGold MS, Pottash AC, Sweeney DR, Kleber HD 1980 — Opiate withdrawal using clonidine (JAMA)
original opioid detox protocol
View StudyKowalchuk et al. 2022 — Lofexidine vs clonidine for opioid withdrawal review
comparative opioid-detox literature
View StudyDetweiler et al. 2016 — Clonidine for PTSD nightmares case series (VA cohort)
second-line PTSD nightmare evidence
View StudyChildress 2023 — Alpha-2 agonists for ADHD review (PMC10204383)
α2A vs α2A/B/C selectivity comparison; clonidine vs guanfacine clinical context
View StudyPsychSceneHub — Guanfacine and clonidine for ADHD: what's the difference
clinical comparison
View StudyRoehrs T, Roth T 2010 — Sleep effects of α2-adrenergic agonists
REM suppression characterization
View StudyDrugs.com — Clonidine full prescribing information
dosing, side effects, interactions reference
View StudyMayo Clinic — Clonidine oral route side effects and dosage
patient-facing reference
View StudyHoehn-Saric et al. 1981 — Clonidine for anxiety disorders (Arch Gen Psychiatry)
early panic / anxiety trial
View StudyAACAP 2007 ADHD Practice Parameter
α2 agonist recommendations in pediatric ADHD treatment
View StudyLatest research
- reviewExploring the potential benefits of clonidine for anxiety disordersAneja, Hollowell, Schwartz 2025 (CNS Spectr) — clonidine α2A agonism modulates NE + glutamatergic pathways; promising for treatment-resistant anxiety and pediatric populations but evidence remains limited by inconsistent efficacy and sedation/hypotension side effects. Calls for large-scale trials. PMID 40376793.
- systematic-reviewClonidine for post-traumatic stress disorder — systematic reviewMarchi, Grenzi, Boks 2024 (Eur J Psychotraumatol) — 10 studies, 569 PTSD patients. Median dose 0.15 mg/day (optimal 0.15-0.20); doses <0.05 mg/day ineffective. Meta-analysis vs prazosin/terazosin showed no difference on nightmares. Sleepiness 8.9%, dizziness 6.3%. Quality very-low to low; no serious AEs.
- reviewThe role of alpha-2 agonists for ADHD in children — a reviewNeuchat et al. 2023 (Neurol Int) — clonidine vs guanfacine for pediatric ADHD; guanfacine more α2A-selective (PFC effect), response rates 50-60%. Common AEs drowsiness/sedation/bradycardia. Cardio monitoring required; useful for stim-intolerant + comorbid tics/autism. PMID 37218982.
How was your experience with this compound?
Anonymous · one vote per session · results below at 5+ votes.
See something off?
Most of this wiki is AI-generated. Suggest a correction, dosing update, or new evidence — we review every submission.